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resumo 
 
 
O cancro da próstata é um dos cancros mais prevalentes e incidentes em 
homens, sendo uma preocupante causa de morte a nível mundial. A ampla 
utilização do antigénio específico da próstata (PSA) no seu rastreio e as 
melhorias na sua terapêutica têm permitido uma diminuição marcada da 
mortalidade. No entanto, o uso do PSA é controverso uma vez que se verifica 
um diagnóstico excessivo e o tratamento de vários casos que, eventualmente, 
não representariam qualquer ameaça para a vida do individuo. Assim, o 
estabelecimento de novos biomarcadores e a descoberta de novos alvos 
terapêuticos para o cancro da próstata constitui um importante desafio 
na atualidade.  
Alterações em várias vias de sinalização têm sido relacionadas com o 
desenvolvimento e a progressão do cancro da próstata. A via do TGFβ é uma 
das vias mais proeminentes no controlo do crescimento da próstata, uma vez 
que contrabalança os efeitos proliferativos dos androgénios. Um dos principais 
mecanismos de regulação da via do TGFβ é a fosforilação reversível, 
executada de modo complementar por proteínas cinases e fosfatases. Uma 
das fosfatases envolvidas na regulação da via do TGFβ é a PPP1.  
A PPP1 é uma fosfatase reguladora de inúmeros eventos celulares. A maioria 
das suas funções envolve a sua ligação a subunidades reguladoras 
conhecidas como PIPs. Recentemente, foi descrita uma 
nova PIP, a TCTEX1D4, que já havia sido referida 
como interactor dos recetores da via do TGFβ. No entanto, pouco se sabe 
acerca da sua função.  
Este trabalho permitiu identificar a TCTEX1D4 como agente inibidor da 
proliferação em células humanas de próstata. A sua atividade parece ser 
modulada através da ligação à PPP1, uma vez que a disrupção do 
complexo TCTEX1D4/PPP1 conduziu a uma maior inibição da proliferação 
celular. Por outro lado, a TCTEX1D4 pode regular indiretamente a atividade da 
PPP1 ao modular a sua localização no interior da célula. Este complexo não 
parece atuar ao nível da migração celular. 
Tendo em conta os presentes resultados, o complexo TCTEX1D4/PPP1 
parece constituir um potencial alvo para o desenvolvimento de novas terapias 
para o cancro da próstata. 
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abstract 
 
Prostate cancer is one of the most prevalent and incident cancer in men, being 
a disquieting cause of men’s death worldwide. The widespread implementation 
of prostate-specific antigen (PSA) screening and the improvements on prostate 
cancer therapy have been leading to a markedly decrease in mortality. 
However, PSA use is controversial since it has been leading to the diagnosis 
and treatment of several prostate cancer cases that would not otherwise cause 
symptoms or threaten man’s life. Hence, the establishment of a panel of 
biomarkers and the discovery of new therapeutical targets for prostate cancer 
is a pressing need. 
Changes in several cell signaling pathways have been associated with de 
onset, development, and progression of prostate cancer. TGFβ signaling 
counterbalanced the mitogenic effects of androgens, thus being one of the 
most prominent pathways involved in controlling prostate growth. Mediators of 
TGFβ signaling pathway are strictly regulated by several mechanisms, among 
which reversible phosphorylation. This process involves a fine equilibrium 
between the action of protein kinases and phosphatases. 
PPP1 is a major serine/threonine phosphatase that regulates numerous cellular 
events, including TGFβ signaling. The majority of its functions are 
accomplished by association with regulatory subunits, known as PPP1-
interacting proteins (PIPs).  
Recently, a novel PIP was found: TCTEX1D4, a dynein light chain protein that 
was already established as an interactor of TGFβ receptors. Its functions, 
nevertheless, remain poorly understood. 
This work identified TCTEX1D4 as an anti-proliferative agent in human prostate 
cells. Also, TCTEX1D4 activity seems to be regulated through binding to PPP1, 
as the disruption of TCTEX1D4/PPP1 complex resulted in enhancement of cell 
proliferation inhibition. Alternatively or in addition, TCTEX1D4 may indirectly 
regulate PPP1 function by modulating its subcellular localization. This complex 
doesn´t appear to play a major role in cell migration. 
Given the results, TCTEX1D4/PPP1 complex may constitute a potential target 
for the development of new prostate cancer therapies.  
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INTRODUCTION 
1.1 OVERVIEW OF THE HUMAN PROSTATE AND PROSTATE CANCER 
1.1.1 ANATOMY AND PHYSIOLOGY OF THE PROSTATE GLAND 
The prostate is an accessory gland of the male reproductive system. As depicted in Figure 
1A, it is located in the pelvis, under the bladder, and surrounding the prostatic urethra [1]. 
As an exocrine gland, the prostate produces a milky secretion, known as prostatic fluid, 
essential for the formation of the seminal fluid (it represents near 30% of the seminal fluid 
volume). The prostatic fluid maintains the fluidity of the seminal fluid, nourishes the 
sperm, and supports the fertilization process [1]. Moreover, the prostate supports the control 
of urine output and ejaculation, and participates in the metabolism of testosterone [2].  
The prostate is constituted by glandular and non-glandular structures. Among the glandular 
tissue, four anatomical zones can be distinguished: (1) the peripheral zone (70% of the 
glandular tissue); (2) the central zone (25% of the glandular tissue); (3) the transition zone 
(5% of the glandular tissue); and (4) the periurethral zone, which encompasses mucosal 
and submucosal glands (Figure 1B) [3]. Prostate glandular structures are embedded in a 
fibromuscular stroma (Figure 1B) [4].  
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These zones present different embryologic origins, histology, function and susceptibility to 
pathological processes is also distinct [5].  
 
Figure 1 | Overview of the human prostate gland localization and anatomy.  
(A) Localization of the human prostate in a sagittal section of the pelvic cavity. (B) Anatomical zones of the human 
prostate gland. [Adapted from 
[6, 7]
]. 
In terms of cellular content, the prostate epithelium contains three main cell types which 
exhibit distinct expression profiles. Secretory luminal cells mostly express androgen 
receptor (AR), cytokeratins 8 and 18, and cluster of differentiation 57 (CD57). They are 
responsible for the production of prostate-specific antigen (PSA), prostatic acid 
phosphatase, and human kallikrein-2. Basal cells express cytokeratins 5 and 14, CD44, and 
other markers at a less extent. They also express low levels of AR and are believed to be 
the proliferative compartment of the prostate. Neuroendocrine cells are androgen-
independent and express chromogranin A and a variety of peptide hormones [8, 9]. 
The growth of the glandular epithelium is influenced by sexual hormones, with emphasis 
to testosterone and dihydrotestosterone (DHT), the most important mitogens for the normal 
prostate. In the classical AR signaling, ligands bind to the AR in the cytosol resulting in its 
translocation into the nucleus where it acts as a transcription factor. AR binds to specific 
sequences of deoxyribonucleic acid (DNA) in the promoter regions of target-genes, known 
as androgen-response elements, and activates genes that, overall, stimulate proliferation, 
differentiation, and secretion [3, 10]. On the other hand, androgens potentiate the activation of 
alternative signaling molecules, including epidermal growth factor (EGF), fibroblast 
growth factor (FGF), transforming growth factor-α (TGFα), and insulin-like growth factor 
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(IGF). Proliferative effects of such molecules are counterbalanced by transforming growth 
factor-β (TGFβ). 
1.1.2 PROSTATE CANCER EPIDEMIOLOGY AND PATHOGENESIS 
The prostate tissue is mentioned as the original site for the two most prevalent diseases of 
elderly men: benign prostatic hyperplasia (BPH) and prostate cancer (PCa) [5]. PCa was 
considered by the Globocan Project 2008 the second most incident cancer in men (only 
excelled by lung cancer), with nearly 900 000 men being affected each year worldwide. It 
was also identified as the sixth leading cause of death from cancer among men worldwide. 
In Portugal, PCa is the most incident and prevalent cancer in men and represents the third 
cause of cancer-related death [11, 12].  
Old age, black ethnicity, and a family history of the disease are the risk factors most 
commonly associated with PCa. The average age at the time of diagnosis is 67 and about 
two-thirds of cases are diagnosed in men aged 65 years and over‒diagnosis before age 40 
is rare. Environmental risk factors such as eating habits, early sexual initiation, and 
sexually transmitted infections are also associated with the development of the disease [13]. 
About 70% of the PCa cases originate in the peripheral zone, 15%-20% in the central zone, 
and only 10%-15% in the transition zone (in contrast to the BPH that mainly develops in 
the transition zone) [14]. 
The cellular origin of PCa has been attributed either to the dedifferentiation and mortality 
acquisition of differentiated luminal cells or to the malignant transformation of prostate 
stem cells that are confined to the basal compartment [15]. These prostate stem cells consist 
of a slowly proliferating population that gives rise to a population of progenitor cells, 
called transient amplifying population, which in turns generate the mature prostatic 
epithelial cells in response to androgens [8]. Although these cells are androgen-sensitive in 
terms of growth, they do not rely on androgens for survival [5]. It has also been observed 
that PCa can arise from basal cells, although the aggressive potential of luminal and basal 
cells populations differs [16].   
Similarly to other cancer types, precancerous lesions seem to occur prior to PCa 
development (Figure 2). Overall, loss of tumor suppressor genes, oncogene activation, and 
epigenetic alterations culminate in the activation of growth factor receptors, signaling 
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mediators, kinases, transcription factors, coregulators, and multiple proteases that enable 
the progression to PCa (Figure 2) [17, 18].  
 
Figure 2 | Stages and processes underlying PCa initiation and development. 
The scheme on the left represents the stages of PCa progression leading to a metastatic and androgen-independent stage. 
On the right, each blue rectangle corresponds to the progression phase on the left. AMACR, alpha-methylacyl-CoA 
racemase; BRCA2, breast cancer 2, early onset; CHEK2, checkpoint kinase 2; EST, E-twenty six; EZH2, enhancer of 
zeste homolog 2; GST-π, glutathione-S-transferase π; HPC1, hereditary prostate cancer 1; HPC2, hereditary prostate 
cancer 2; miRNAs, microRNAs; MSR1, macrophage scavenger receptor 1 gene; p53, protein 53; PTEN, phosphatase and 
tensin homologue; Rb, retinoblastoma tumor suppressor gene; RNASEL, ribonuclease L (2',5'-oligoisoadenylate 
synthetase-dependent); STAT3, signal transducer and activator of transcription 3; TMPRSS2, transmembrane protease 
serine 2. [Adapted from 
[18]
]. 
 
The major problem arising from PCa is its propensity to metastasize. A large number of 
specific molecular mechanisms lead to local invasion, extravasation and distal migration 
from the primary site and subsequently to endothelial attachment, transmigration and site-
specific establishment of metastases at secondary sites, usually at the bone, lung or liver 
(Figure 2) [19, 20]. Of extreme importance is the down-regulation of cell-cell and cell-matrix 
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characteristics, which enable malignant cells to become motile, and their ability to destroy 
the extracellular matrix through degradative enzymes [20]. 
1.2 TGFβ SIGNALING IN PROSTATE CANCER 
1.2.1 TGFβ SIGNALING PATHWAY OVERVIEW 
TGFβ is a multifunctional cytokine that belongs to the TGFβ superfamily, which also 
includes bone morphogenetic proteins (BMPs), activins/inhibins, growth differentiation 
factors (GDFs), and the anti-müllerian hormone (AMH), among others. TGFβ superfamily 
members have been implicated in numerous behavioral aspects of cells, including 
proliferation, differentiation, apoptosis, and motility [21-24]. 
The adult human prostate mostly expresses three TGFβ isoforms: TGFβ1, the most 
abundant and ubiquitously expressed isoform, TGFβ2, and TGFβ3 [24, 25].  
TGFβ ligands are synthesized as latent pre-pro-peptides with high molecular weight that 
encompass a longer N-terminal pro-peptide (latency-associated peptide, LAP) followed by 
a shorter C-terminal mature polypeptide. During the secretory pathway, the pro-peptide is 
proteolytically cleaved from the mature peptide in the trans-Golgi apparatus by furin-like 
proteases, but they remain noncovalently linked [24]. This complex might also associate 
with latent TGFβ binding proteins, forming a large latent complex, which is important for 
the regulation of TGFβ bioavailability. In the extracellular matrix, via further proteolytic 
cleavage and/or structural modification of the complex, TGFβ is converted to a dimeric 
active cytokine that is able to bind with high-affinity to cell surface receptors [23, 24, 26].  
TGFβ signals mainly through interaction with the extracellular domain of two types of 
transmembrane serine/threonine kinase receptors: the type I TGFβ receptor (TβRI, also 
known as activin receptor-like kinase, ALK) and the type II TGFβ receptor (TβRII). In 
humans, seven TβRI and five TβRII are currently characterized. All of them are constituted 
by three regions: (1) an extracellular N-terminal domain responsible for TGFβ binding, (2) 
a transmembrane domain; and (3) a cytoplasmic C-terminal domain which incorporates the 
catalytic center. Unlike TβRII, which are constitutively active, TβRI requires 
phosphorylation of the GS domain (a serine and threonine rich region) to become active. 
Therefore, ligands bind specifically to TβRII that, in turn, phosphorylates TβRI in the 
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cytosolic GS domain and thereby activates it. Afterwards, the active heterotetrameric 
receptor complex activates downstream signaling pathways [23, 24].  
TGFβ signaling is modulated by coreceptors that lack the kinase domain, as betaglycan 
(also referred as type III TGFβ receptor, TβRIII) and endoglin (ENG) [24]. Both receptors 
are on the cytoplasmic membrane but can also be found in a soluble form [23]. TβRIII, the 
largest and most abundant, binds all TGFβ isoforms; on the other hand, ENG primarily 
binds TGFβ1 and TGFβ3 [24].  
As observed in other signaling pathways, TGFβ can activate two intracellular pathways: 
the canonical and the non-canonical (Figure 3).  
 
Figure 3 | TGFβ canonical and non-canonical signaling pathway. 
In the canonical signaling pathway (left), R-Smads are activated by serine phosphorylation and form a complex with Co-
Smad. The complex is translocated into the nucleus where it can bind to specific transcription factors (TF) and induces 
the transcription of TGFβ-dependent genes. On the other hand, TGFβ can activate alternative signaling pathways (right). 
Abl, Abelson tyrosine-protein kinase; Cdc42, cell division control protein 42 homolog;  ERK, extracellular signal-
regulated kinase; FAK, focal adhesion kinase; JNK, stress-activated protein kinase; MAPK, mitogen-activated protein 
kinase; NFκB, nuclear factor κB; P, phosphate; PKB, protein kinase B; PTK, protein tyrosine kinase; Rac1, Ras-related 
C3 botulinum toxin substrate 1; RhoA, Ras homolog gene family, member A.  
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Canonical signaling pathway effectors are classified as receptor-regulated Smads (R-
Smads), common Smad (Co-Smad) and inhibitory Smads (I-Smads). R-Smads include 
Smads 1/2/3/5/8 and are direct targets of TβRI, propagating signals towards the nucleus. 
Co-Smad, or Smad4, forms heterotrimeric complexes with R-Smads and aids the 
propagation of the signal. Signal is transmitted in either two ways: (1) via Smad2/3, which 
are phosphorylated by the TβRI ALK4/5/7, mainly activated by TGFβ, nodal, activins, and 
some GDFs; or, (2) via Smad1/5/8, which are phosphorylated by the TβRI ALK1/2/3/6, 
mostly activated  by BMPs, AMH, and some GDFs. Upon formation of the heterotrimeric 
complex, it is translocated to the nucleus via microtubules and dyneins, where it modulates 
the expression of several genes (Sp1, Id1, Id2, and Myc). I-Smads, Smads 6 and 7, 
antagonize the TGFβ signaling: (1) through receptor binding, avoiding R-Smads/receptor 
interaction and signal propagation; (2) by preventing the formation of R-Smad/Co-Smad 
complexes; (3) by targeting receptors to degradation; or (4) through binding to DNA and 
Smad complexes in the nucleus, blocking the signal [21, 23].  
TGFβ can also activate non-canonical pathways, and thus participate in cell proliferation, 
differentiation, migration, apoptosis, epithelial to mesenchymal transition, and matrix 
formation [24].  
1.2.2 REGULATION OF THE TGFβ SIGNALING PATHWAY 
TGFβ signaling is tightly regulated due to the TGFβ critical role on normal cell behavior 
and its involvement in pathological conditions. This regulation is observed at diverse levels 
of the pathway, involving ligands, receptors, and Smads. As mentioned above, TGFβ 
ligands are synthesized as a precursor protein that contains a LAP able to maintain the 
ligands in a latent form; ligands access to the kinase receptors is modulated by coreceptors; 
and I-Smads inhibit the signaling in different ways [27].  
Furthermore, the internalization and recycling of ligand-receptor complex are important 
steps in the regulation of the signal [27]. Activated receptor endocytosis occurs in early 
endosomes and involves the Smad anchor for receptor activation (SARA) in cooperation 
with the regulatory adaptor cytoplasmic promyelocytic leukemia tumor suppressor protein. 
SARA facilitates the phosphorylation and activation of the TβRI through recruitment of 
Smad2/3. Alternatively, TGFβ receptors degradation can occur via caveolae, characterized 
by the presence of caveolin-1 and key regulatory proteins, such as Smad7 and Smurf [26].  
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Additional TGFβ signaling regulators are motor proteins that are associated with 
microtubules. For instance, R-Smads, either before or after phosphorylation, can interact 
with kinesin and dynein light chain proteins to accomplish their trafficking.  
TGFβ receptors and Smads are also controlled by a number of post-translational 
modifications, such as reversible phosphorylation, ubiquitination, SUMOylation and 
acetylation [28]. TGFβ pathway is activated by a sequence of phosphorylation reactions; 
therefore, dephosphorylation of TGFβ signaling intervenients constitutes a counterbalance 
mechanism that limits the duration and intensity of the signal, contributing to its 
termination [29]. 
1.2.3 IMPLICATIONS OF THE TGFβ SIGNALING IN HUMAN PROSTATE CANCER 
TGFβ has a dichotomous function in human cancers. In spite of its physiological inhibitory 
effects and its role as tumor suppressor in early tumorigenesis, it also acts as a tumor 
promoter in later stages of tumor progression [18, 30]. However, the precise mechanism 
underlying this phenomenon remains poorly defined.  
TGFβ has been shown to directly or indirectly mediate several cancer hallmarks, such as 
self-sufficiency in growth factors, insensitivity to anti-growth signals, loss of apoptotic 
potential, limitless replicative potential, evasion of the immune system, tissue invasion and 
metastasis formation, and sustained angiogenesis [25]. The exact cellular effect, nonetheless, 
depends on the cell type and physiological conditions [24].  
As observed in other types of cancer, PCa cells become resistant to the inhibitory effects of 
TGFβ, while maintaining some TGFβ-mediated responses, such as the stimulation of 
motility [20].  
PCa cells express high levels of TGFβ1. These increased levels aid tumorigenesis by acting 
directly on the tumor cells themselves and indirectly by stimulating angiogenesis and 
suppressing the immune system [31, 32]. Thus, TGFβ1 levels correlate with high Gleason 
Score, bone metastasis formation, angiogenesis and poor clinical outcome [5]. 
Regarding TGFβ receptors, there is a decrease in both TβRI and TβRII [33]. Actually, circa 
30% of PCa specimens exhibit downregulation or absence of a TGFβ receptor [20]. The 
absence of these receptors in PCa cells leads to growth inhibition resistance, enabling a 
clonal expansion of these cells [33-35].  
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Several studies have also reported a loss of TβRIII, mainly during metastasis formation. 
This loss is associated with disease state, metastatic disease, and PSA recurrence [36]. 
Remarkably, other studies demonstrated that ENG suppresses human PCa metastasis. 
Indeed, ENG expression facilitates ALK2-mediated Smad1 activation, thereby suppressing 
TGFβ-mediated increases in PCa cell motility. Contrastingly, with PCa progression, the 
decrease of ENG expression contributes to the predomination of ALK5-Smad3 pathway, 
thus promoting cell motility [37].  
The activity of Smad intracellular signaling in PCa has also been lengthily explored. In the 
earlier stages of PCa development, ALK2-Smad1/5/8 signaling prevails to increase the 
growth and neovascularization. On the other hand, in advanced PCa this signaling pathway 
is overcame by ALK5-Smad2/3 signaling, leading to the enhancement of invasiveness, 
migration and metastasis formation [38, 39]. 
The increasing evidence of the relevance of TGFβ signaling in PCa carcinogenesis has led 
to the challenging idea that the target of its mediators should provide a mechanism of 
controlling tumor progression [40]. Indeed, preclinical studies using antisense approaches 
and antibodies to target TGFβ mechanisms, as well as the use of small molecule inhibitors 
that act through TGFβ receptors have been quite promising [41]. Also, genistein, that was 
found to act through Smad1 in an ALK2-dependent way to suppress PCa cell invasion, is 
already ongoing phase II clinical trials [42]. 
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1.3 PHOSPHOPROTEIN PHOSPHATASES 
1.3.1 OVERVIEW ON REVERSIBLE PROTEIN PHOSPHORYLATION 
Reversible protein phosphorylation is the most common post-translational modification 
controlling intracellular metabolic mechanisms in eukaryotic cells. Phosphorylation of a 
protein may induce conformational changes in the protein, create binding sites for effector 
molecules, activate or inhibit enzymes, alter the association/dissociation properties of 
protein complexes, stabilize proteins, target proteins to degradation, and promote/inhibit 
the movement of subcellular components [43]. Unsurprisingly, deregulation of such 
regulatory system underlies many pathological states (e.g. cancer, diabetes and 
neurodegenerative conditions) [44]. 
Phosphorylation corresponds to the addition of a phosphate group to an amino acid side 
chain of a protein by a protein kinase; the phosphate group is normally provided by an 
adenosine-5'-triphosphate (ATP) molecule and the most common targets are the hydroxyl 
groups of serine, threonine, or tyrosine. Dephosphorylation is the opposite reaction, in 
which a phosphatase catalyzes the removal of the phosphate group from the 
phosphoprotein [45].  
The first reference to this process remounts to the late 20s, when Cori and Cori started their 
investigation about glycogenolysis and glycogenesis (actually known as Cori cycle). The 
enzymatic intervenients in these reactions were later defined by Edmond Fischer and 
Edwin Kreb as being a protein kinase (phosphorylase a; phosphorylase kinase) and a 
protein phosphatase (phosphorylase b; phosphorylase phosphatase) [45, 46]. Therefore, 
reversible protein phosphorylation reactions are catalyzed by kinases and phosphatases in a 
counterbalanced way [44]. 
In human genome, nearly 3% of all eukaryotic genes encode protein kinases or, at less 
extent, protein phosphatases; there are only 150 phosphatases comparing to the near 500 
protein kinases [44, 47].  
According to the substrate specificity, protein phosphatases are divided into two main 
groups: serine/threonine protein phosphatases (STPPs) and protein tyrosine phosphatases 
(PTPs) [45]. Each group includes several families and subfamilies (Figure 4). 
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Figure 4 | Families of protein phosphatases (PPs).  
Protein phosphatases are divided into two major groups: PTPs and STPPs. PTPs include the tyrosine-specific PPs, which 
can be either cytosolic or receptor PTPs, and the dual-specificity phosphatases, capable of dephosphorylating serine, 
threonine, and tyrosine residues. STPPs comprise three gene families: protein phosphatases Mg2+- or Mn2+-dependent 
(PPMs), TFIIF-associating C-terminal domain (CTD) phosphatases (FCPs), and phosphoprotein phosphatases (PPPs). 
PPMs include Mg2+-dependent PPs, such as pyruvate dehydrogenase and PPM1. FCPs include FCP1 as well as small 
CTD phosphatases (SCPs). PPPs family encompasses PPP1-7.  
1.3.2 PPP1 AND ITS INTERACTING PROTEINS ON PROSTATE CANCER 
Phosphoprotein phosphatase 1 (PPP1) is a major STPP involved in a wide range of cellular 
processes, including cell division, apoptosis, protein synthesis, metabolism, cytoskeletal 
reorganization, and regulation of membrane receptors and channels [45, 48, 49].  
PPP1 holoenzymes exhibit a highly conserved catalytic subunit (PPP1C). In humans, 
PPP1C is encoded by three genes, resulting in the isoforms PPP1CA, PPP1CB and 
PPP1CC (which can form PPP1CC1 and PPP1CC2 by tissue-specific alternative splicing). 
With exception of PPP1CC2, which is testis-enriched and sperm-specific, PPP1 isoforms 
are ubiquitously expressed although their expression levels and subcellular localization 
vary within different cell types [47, 48]. 
PPP1C binds to a number of regulatory subunits, known as PPP1 interacting proteins 
(PIPs). PIPs allow the versatility of PPP1 by modulating its subcellular localization and 
substrate affinity. Almost all PIPs share a short and degenerated RVxF motif, a primary 
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docking site that binds to a hydrophobic groove on a surface behind the PPP1C active    
site [44]. 
Several PIPs have been identified and actually more than two hundred PIPs are recognized 
as modulators of PPP1 subcellular localization and activity [44, 48-50]. Therefore, increasing 
attention has been given to the identification and characterization of PIPs not only to 
establish PPP1 functions but also to understand its role in pathologic conditions. For 
instance, PPP1-PIP complexes were shown to regulate two major tumor suppressors, p53 
and retinoblastoma protein (pRb) [51, 52]. 
PPP1/PIP complexes have been identified as intervenients on PCa. Fer is a tyrosine kinase 
whose levels are significantly higher in PCa [53]. Upregulation of Fer in PCa cells leads to 
the inactivation of PPP1, resulting in the hyperphosphorylation of pRB and, thus, 
carcinogenesis promotion [54, 55].  
Caveolin-1, an integral membrane protein, is overexpressed in PCa cells and is associated 
with the disease progression [56]. It was shown to inhibit PPP1, leading to the increase of 
pyruvate dehydrogenase lipoamide kinase isozyme 1 (PDK1), PKB, and ERK1/2 activities. 
Consequently, caveolin-1 is able to maintain Akt signaling activated and sustain the 
activation of downstream oncogenic Akt targets, increasing the cell survival [57].  
Chen and colleagues observed the interaction between PPP1 and AR: (1) PPP1 inhibition 
enhanced proteasome-mediated AR degradation; (2) PPP1 overexpression increased AR 
expression and markedly enhanced AR transcriptional activity in PCa cells. PPP1 regulates 
AR stability and nuclear localization through dephosphorylation of Ser-650. Thence, AR 
may function as a PPP1 regulatory subunit, mediating PPP1 recruitment to chromatin, 
where it can modulate transcription and splicing [58]. 
Recently, PPP1/nuclear inhibitor of protein phosphatase 1 (NIPP1) complex was described 
as a regulator of PCa cells directional migration [59].  
As imbalances in protein phosphorylation system underlie numerous pathogenic processes, 
modulation of kinases and phosphatases activity might be an attractive therapeutical target 
[18]. The targeting of kinases has been widely explored, but efforts are now being made by 
pharmaceutical companies to also investigate the role of phosphatases. However, targeting 
a specific phosphatase has been associated with severe secondary effects, as nephrotoxicity 
and hepatotoxicity. For this reason, the adequate option seems to be targeting PIPs instead, 
as they are more event, tissue and subcellular compartment specific [44]. Two targeted 
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PPP1/PIP complexes have already been described. The PIPs involved are the growth arrest 
and DNA damage-inducible protein 34 (GADD34) and histone deacetylases (HDACs). 
PPP1/GADD34 complex is diminished in cells treated with salubrinal – a small molecule 
that protect the cell from ER-stress-induced apoptosis; and trichostatin A disrupts 
PPP1/HDAC6 complex in glioblastoma and PCa cells [60]. Hence, to unravel the complete 
PPP1 interactome in PCa is of crucial importance to establish potential new therapeutical 
targets.  
1.3.3 TGFβ SIGNALING PATHWAY REGULATION BY PPP1 
Despite the longstanding suspected influence of protein phosphatases in the regulation of 
TGFβ signaling, concrete data only started to emerge recently. 
PPP1-PIP complexes have been implicated in the TGFβ signaling. By being targeted 
through the PPP1-docking protein SARA, PPP1C dephosphorylates TβRI, resulting in the 
attenuation of the signal [61]. This targeting also involves Smad7 and GADD34 [62]. 
Moreover, Smad7 may recruit PPP1C to ALK1 thereby mediating its dephosphorylation 
and inactivation in endothelial cells [63].  
Recently, a novel PIP has been identified using a yeast two-hybrid screen from a human 
testis complementary DNA (cDNA) library: t‐complex testis expressed protein 1 domain 
containing 4 (TCTEX1D4), a dynein light chain family member that has been shown to 
have a role in the TGFβ cascade [64]. 
1.4 TCTEX1D4, A NOVEL PPP1-INTERACTING PROTEIN 
1.4.1 OVERVIEW ON DYNEINS CHARACTERIZATION  
Dyneins are multimeric molecular motor complexes that translocate cellular cargo along 
microtubules, minus-end directed. They are composed of four subunits: dynein heavy 
chains (DHCs), intermediate chains (DICs), light intermediate chains (DLICs), and light 
chains (DLCs) (Figure 5). DHCs, which exhibit both ATPase and microtubule motor 
activities, associate with DICs and DLCs to form the basal cargo-binding domain of the 
enzyme [65, 66]. DLCs bind to the cargo and determine the cargo-specificity [67]. DICs and 
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DLICs modulate and regulate the complex activity. More specifically, both mediate cargo 
binding to dynein, and DICs also regulate the motion by changing motor activity [66, 68].  
According to their location, dyneins can be classified as flagellar/axonemal or cytoplasmic 
(Figure 5) [65, 69]. Flagellar/axonemal dyneins empower the movement of eukaryotic cilia 
and flagella [68]. Cytoplasmic dyneins associate to diverse protein, RNA-containing 
complexes, and cellular organelles, such as lysosomes, endosomes and components of the 
Golgi apparatus, and are responsible for their retrograde transport [68]. 
 
Figure 5 | Organization of cytoplasmic dynein complex.  
Dyneins are composed by a homodimer of heavy chains, which forms the motor domain, and smaller accessory subunits 
(light chain, light intermediate chain, and intermediate chain) with two copies of each. 
1.4.2 TCTEX1D4, AN INTERACTOR OF PPP1 AND TGFβ RECEPTORS 
DLCs are divided into three families: LC8, LC7/roadblock and TCTEX1/TCTEX2 [69]. 
TCTEX1D4 is a novel cytoplasmic DLC that belongs to the TCTEX1 protein family. It is 
expressed in a wide variety of cells and tissues, such as vascular endothelial and smooth 
muscles cells, placenta, testis, and several tumor cell lines [67]. 
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TCTEX1D4 gene locates in the chromosome 1p34.1 and the gene product has 221 amino 
acids, being composed by two domains:  the disordered domain (residues 1–120) and the 
globular (residues 121–221) domain, which is common to all family members. The 
disordered domain presents putative serine phosphorylation sites for several kinases, 
including for protein kinase A, B and C, cyclin-dependent kinase 1 and glycogen synthase 
kinase 3 [67, 70].  
As observed in the majority of the PIPs, the RVxF motif (RVSF) was found in the residues 
90-93 of TCTEX1D4, and evidences suggest that its dephosphorylation is a crucial post-
translational modification for TCTEX1D4 regulation [70]. 
In what concerns TCTEX1D4 functions, the current knowledge is still limited. Besides 
TCTEX1D4 interaction with PPP1, it was also identified as a partner for receptors of the 
TGFβ signaling pathway [67]. Actually, TCTEX1D4 can bind to the cytoplasmic domain of 
endoglin and to TβRII, forming a multimeric complex mainly located at the cell 
membrane. Interestingly, TCTEX1D4 showed an inhibitory activity on the TGFβ1-induced 
signaling in liver and lung cells, perhaps because of the blockage of both receptors 
internalization and their consequent longer retention time in the membrane [67]. 
Furthermore, it may have a possible role in cell-to-cell junctions and microtubule 
dynamics. The presence of binding sites for APC/C, cyclins and MAPK also suggests that 
it possibly play a regulatory role in proliferation, differentiation, and cell cycle [70].  
 
 
 
 
 
 
 
 
 
16 
 
17 
 
 
AIMS 
The identification of TCTEX1D4 as a PIP and as a TGFβ1-induced signaling inhibitor 
gave rise to the hypothesis that TCTEX1D4 dephosphorylation by PPP1 may play a critical 
role in the TGF-β signaling regulation. 
Taking into account the role of TGFβ signaling in PCa progression, this study is 
specifically concerned with the effect of TCTEX1D4 dephosphorylation in such signaling 
and, consequently, on the cancer cells proliferation and metastasis formation. 
Preliminary results from our laboratory confirmed the presence of both TCTEX1D4 and 
PPP1 in normal and PCa cells. Hence, four human prostate epithelial cell lines will be 
used: RWPE-1, PNT-2, PC-3, and LNCaP.  
To achieve the main goal, the specific aims of this thesis include to: 
1. Optimize the growth conditions of human prostate cell lines: RWPE-1, 
PNT-2, PC-3, and LNCaP; 
2. Optimize transfection conditions of RWPE-1, PNT-2, PC-3, and 
LNCaP cell lines with Myc-TCTEX1D4 and Myc-TCTEX1D4- RVSA; 
3. Optimize TGFβ treatment for PNT-2, PC-3, and LNCaP cell lines; 
4. Determine the effect of TCTEX1D4/PPP1 in prostate cell proliferation; 
5. Determine the role of TCTEX1D4/PPP1 in prostate cell migration.
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MATERIALS AND METHODS 
All the experiments required to accomplish the aims of this thesis were carried out in the 
Signal Transduction Laboratory, Center for Cell Biology, University of Aveiro (Aveiro, 
Portugal).  
Additional information about the composition of the solutions and materials used in the 
experiments is provided in the appendix. 
3.1 HUMAN PROSTATE CELL LINES 
RWPE-1 (ATCC, Barcelona, Spain) are normal adult human prostate epithelial cells 
derived from the peripheral zone. PNT-2 cell line (kindly provided by Dr. Ricardo Pérez-
Tomás, University of Barcelona, Spain) was established by immortalization of normal 
adult prostatic epithelial cells, through transfection with a plasmid containing the genome 
of Simian vacuolating virus 40 (SV40) with a defective replication origin. PNT-2 may be 
considered a preneoplastic model as they retain many of the features of well-differentiated 
prostate epithelial cells despite not being completely normal. LNCaP and PC-3 (kindly 
provided by Dr. Rui Medeiros, Portuguese Institute of Oncology of Porto, Portugal) are 
human PCa cell lines. LNCaP is a human PCa androgen-sensitive cell line established from 
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a metastatic lesion in the left supraclavicular lymph node. PC-3 is a highly metastatic and 
androgen-independent human PCa cell line established from bone metastasis of grade IV. 
All the cell lines were tested for Mycoplasma and the results were negative.  
3.2 WILD TYPE AND MUTANT TCTEX1D4 CDNAS 
Myc-TCTEX1D4 (wild type) and Myc-TCTEX1D4-RVSA (mutant) plasmids were 
already available at the laboratory [64]. Briefly, in Myc-TCTEX1D4, the cDNA of 
TCTEX1D4 was PCR-amplified and inserted into EcoRI/XhoI sites of pCMV-Myc vector 
(Clontech, Saint Germain-en-Laye, France). Myc-TCTEX1D4-RVSA was created by 
mutating the last amino acid of the PPP1BM RVSF in the TCTEX1D4 cDNA to an 
alanine. This resulted in the disruption of the PPP1BM. Empty pCMV-Myc vector (Figure 
18 in Appendix) was used as control. 
Plasmids were purified according to the “Wizard Plus Maxipreps DNA Purification 
System” (Promega, Southampton, UK) manufacturer’s instruction. Plasmids obtained were 
stored at -20°C (Table 1). 
 
Table 1 | Plasmids obtained after purification by maxiprep.  
For each cDNA, two sets of plasmids were obtained with different 
concentrations and purities. 
Myc-TCTEX1D4 Myc-TCTEX1D4-RVSA 
Concentration Purity Concentration Purity 
903.0 ng/μl 1.93 1143.3 ng/μl 1.91 
919.3 ng/μl 1.92 1109.5 ng/μl 1.93 
3.3 TGFβ1 
TGFβ1 (Sigma-Aldrich, Sintra, Portugal) was reconstituted using 0.2 μm filtered 4 mM 
HCl (Sigma-Aldrich, Sintra, Portugal) containing 1 mg/ml of BSA (Nzytech, Lisboa, 
Portugal). Stock solution (1 μg/ml) was stored at -20°C.  
A pilot experiment was carried out in both serum and serum-free conditions to test the 
effect of diverse TGFβ1 concentrations in prostate cells proliferation. Given the results, the 
subsequent experiments were carried out using 5 ng/ml or 20 ng/ml of TGFβ1. 
The role of TCTEX1D4/PPP1 complex in cell proliferation and migration Materials and Methods 
 
 
21 
    
3.4 ANTIBODIES 
Primary antibodies used include the PPP1CC1 rabbit polyclonal antibody (homemade, 
CBC3C), which recognizes the C-terminal sequence of PPP1CC1 isoform, the c-Myc 
mouse monoclonal antibody (Invitrogen, Madrid, Spain) that recognizes the Myc-tag, and 
the primary antibody against the C-terminal of TCTEX1D4 (homemade, CBC8C) (Table 3 
in Appendix).  
Secondary antibodies used include Texas Red goat anti-mouse (Invitrogen, Madrid, Spain) 
and Infrared IRDye-labeled anti-rabbit specific to Li-Cor’s Odyssey Infrared Imaging 
System (LI-COR Biosciences, Bad Homburg, Germany) (Table 3 in Appendix). 
3.5 CELL LINES MAINTENANCE 
RWPE-1 were cultured in Keratinocyte Serum Free Medium (K-SFM; Gibco, Madrid, 
Spain) supplemented with 5 ng/ml of epidermal growth factor (EGF; Gibco, Madrid, 
Spain), 0.05 mg/ml of bovine pituitary extract (BPE; Gibco, Madrid, Spain) and 1% (v/v) 
penicillin/streptomycin/amphotericin solution (Gibco, Madrid, Spain). PNT-2, LNCaP, and 
PC-3 were cultured in RPMI-1640 Medium (Gibco, Madrid, Spain) supplemented with 
10% (v/v) fetal bovine serum (FBS; Gibco, Madrid, Spain) and 1% (v/v) 
penicillin/streptomycin amphotericin solution. The cell lines were maintained in a 5% CO2 
humidified incubator at 37°C. Media renewal occurred every 2‒3 days. 
3.6 THAWING CELLS AND CRYOPRESERVATION  
Complete growth media were previously placed in the incubator for 15 minutes. A vial of 
frozen cells was retrieved from liquid nitrogen freezer. The vial was rapidly thawed by 
gently agitation in a water bath set at 37°C. Cells were immediately centrifuged at 1000 
rpm, 22°C, for 3 minutes (LNCaP and PC-3) or for 7 minutes (RWPE-1). Pellet was then 
resuspended in 1 ml of complete growth medium, transferred to a 60 mm culture dish 
(VWR International, Carnaxide, Portugal), and incubated in a 5% CO2 humidified 
incubator at 37°C.  
For cryopreservation, cells were resuspended in cryopreservation medium (complete 
growth medium supplemented with 5% (v/v) dimethyl sulfoxide (DMSO)). 
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3.7 TRYPAN BLUE ASSAY FOR CELL PLATING 
In order to plate the same amount of cells per well, cells were initially counted using the 
dye exclusion assay Trypan Blue (Sigma-Aldrich, Sintra, Portugal). Briefly, the principle 
of this assay lies on the fact that living cells with an intact cytoplasmic membrane do not 
incorporate the reagent, while dead cells retain the dye and stain blue. 
Briefly, 10 μl of 0.4% Trypan Blue were added to 90 μl of cell suspension. The unstained 
(viable) cells were counted in a Neubauer chamber and cell concentration was calculated 
for cell plating. 
3.8 COATING OF PLATES AND COVERSLIPS FOR CELL ATTACHMENT 
Before seeding cells, an 18 mm coverslip was introduced in each well of a 6-well plate. 
Poly-L-ornithine (Sigma-Aldrich, Sintra, Portugal), 0.1 mg/ml, was added to each well for 
5 minutes. At that point, poly-L-ornithine was removed and the plate was allowed to dry. 
The plates were then washed with autoclaved water and completely dry before use.  
3.9 TRANSIENT TRANSFECTION WITH LIPOFECTAMINE 2000  
To assess the effect of TCTEX1D4/PPP1 complex in cell proliferation and migration, 
human prostate cell lines were transiently transfected with the cDNAs mentioned above 
using Lipofectamine 2000 (Invitrogen, Madrid, Spain) transfection reagent.  
Lipofectamine 2000 is a cationic-lipid transfection reagent that complexes with negatively 
charged nucleic acids. The positive charge of liposomes masks the negative charge of 
nucleic acids, enabling their interaction with the cell membrane and resultant endocytosis 
of the complexes into the cytoplasm.  
A pilot experiment was performed to select the most accurate conditions for human 
prostate cells transient transfection. Different amounts of DNA and transfection times were 
tested following the manufacturer’s instructions. Transfection efficiency (TE) was assessed 
by Western blot and immunofluorescence analysis. 
In order to have 70-90% confluence at the time of transfection, cells (5x10
5
/well) were 
seeded in 6-well plates with complete growth medium (2 ml/well), 24 hours prior to 
transfection. At the time of transfection, cell medium was changed to 2 ml/well of Opti-
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MEM Reduced Serum Medium (Invitrogen, Madrid, Spain). To proceed with transfection, 
3 µg of DNA were diluted in 250 μl of Opti-MEM Reduced Serum Medium. After being 
gently mixed, 6 µl of Lipofectamine 2000 were diluted in 250 μl of Opti-MEM Reduced 
Medium and incubated for 5 minutes at room temperature (RT). Next, the diluted DNA 
was added to the diluted Lipofectamine 2000. The mixture was incubated for 25 minutes at 
RT to allow complexes formation. The 500 µl of transfection mix was added dropwise to 
each well and the plates were gently agitated. Then, the 6-well plates were incubated at 
37ºC in a humidified incubator in an atmosphere of 5% CO2. After 4 hours of incubation, 2 
ml of growth medium without antibiotics were added to each well and the plates returned 
to the incubator to complete 24 hours of transfection. 
3.10 CELL COLLECTION AND QUANTIFICATION OF PROTEIN CONTENT 
Cell medium was removed and cells were collected with 150 µl of 1% boiling sodium 
dodecyl sulfate (SDS; Sigma-Aldrich, Sintra, Portugal). Cell lysates were boiled for 10 
minutes and sonicated for 15 seconds. The total protein content of the samples was then 
determined by the Pierce’s bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, 
Bremen, Germany), following the manufacturer’s instructions.  
The principle of this assay relies on two subsequent chemical reactions: (1) the biuret 
reaction that involves the reduction of Cu
2+
 to Cu
+
, being the amount of Cu
2+
 reduced 
proportional to the quantity of protein present in the solution; (2) the chelation of two 
molecules of BCA with each Cu
+
 ion primarily formed, resulting in the formation of a 
purple-colored water-soluble complex that absorbs light at a wavelength of 562 nm. The 
absorbance at 562 nm is linear with increasing protein concentration over a working range 
of 20-2000 μg/ml. Total protein concentration of each sample was determined through a 
standard curve prepared by plotting bovine serum albumin (BSA) absorbance vs. BSA 
standard concentration. The standards protein concentrations were prepared in a 96-well 
plate as described in Table 4 (Appendix). 
Each sample was prepared, in a well of the 96-well plate, by adding 5 μl of the sample to 
20 μl of 1% SDS. The working reagent (WR) was prepared by mixing the BCA reagent A 
with BCA reagent B in a 50:1 proportion, and 200 µl of this mixture were added to both 
standards and samples wells. The 96-well plate was incubated at 37ºC for 30 minutes. 
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After briefly cooled at RT, the absorbance at 562 nm was immediately measured using the 
microplate reader Infinite M200 (Tecan, Barcelona, Spain). 
3.11  WESTERN BLOTTING  
After mass normalization, samples were subjected to SDS polyacrylamide gel 
electrophoresis (SDS-PAGE), which enables the migration of proteins according to their 
molecular weight, and were subsequently transferred into nitrocellulose membranes. 
Samples were prepared by adding 1% SDS and 4X loading buffer to the protein content of 
each sample, and run in a 15% gel at 200 V (composition of the gels are stated in 
appendix). Afterward, proteins were electrotransferred onto nitrocellulose membranes at 
200 mA. The resultant membranes were hydrated in 1X tris buffered saline (TBS) for 5 
minutes and blocked with a solution of 5% non-fat milk in 1X TBS with tween (TBST) for 
1 hour. Membranes were then incubated with the primary antibody (diluted in 3% non-fat 
milk/1X TBST) for 2 hours, washed three times in 1X TBST, and incubated with the 
appropriate secondary antibody (also diluted in 3% non-fat milk/1X TBST) for 1:30 hours. 
After two washing steps with 1X TBST and one with 1X TBS, 10 minutes each, 
membranes were scanned in Li-Cor’s Odyssey Infrared Imaging System (LI-COR 
Biosciences, Bad Homburg, Germany). 
3.12 IMMUNOFLUORESCENCE  
Coverslips were transferred to a new 6-well plate with 1 ml/well of 1X phosphate buffered 
saline (PBS; Thermo Scientific, Bremen, Germany). PBS was removed and 1 ml of 4% 
paraformaldehyde was added for 30 minutes. After two washing steps with 1X PBS, 
coverslips were permeabilized in 500 µl of 0.2 TRITON X-100 (diluted in 1X PBS) for 10 
minutes, and blocked in 50 µl of 1X PBS–3% BSA for 30 minutes. The blocking solution 
was removed and coverslips were incubated with 50 µl of the primary antibody, previously 
diluted in 1X PBS–3% BSA, for 2 hours, and then with the respective secondary antibody, 
previously diluted in 1X PBS–3% BSA, for 1 hour. After addition of the secondary 
antibody, procedures were carried out in a dark environment. Coverslips were mounted 
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onto microscope slides using Vectashield Mounting Medium with DAPI (Vector 
Laboratories, Lisboa, Portugal) and sealed for microscope visualization.  
Images were acquired by epifluorescence microscopy using an Olympus IX-81 motorized 
inverted microscope equipped with LCPlanFl 20x/0.40 objective lens. 
3.13 PROLIFERATION ASSAY 
Cell proliferation was measured with the cell viability indicator alamarBlue (AB; 
Invitrogen, Madrid, Spain), used for quantitative measurement of cell viability and 
cytotoxicity. The active component of AB is resazurin, a nontoxic, cell permeable, and 
almost non-fluorescent compound. Viable cells uptake resazurin and reduce it, 
continuously, to resorufin, a very bright red fluorescence compound. Henceforth, the 
fluorescence and color of the cell medium is proportional to the extent of the reaction and 
consequently to the number of living cells. 
Cells were trypsinized and centrifuged at 1000 rpm for 3 minutes at 22°C. After cell 
resuspension in serum-free medium, cells were counted as s 
ated in 3.4., and 2x10
3
 cells/well were plated in a 96-well plate containing 100 μl/well of 
the same growth medium. Cells were incubated in a 5% CO2 humidified incubator at 37°C 
for 4 hours to let cells adhere. Afterward, TGFβ1 (5 or 20 ng/ml) were added to each well 
or, as controls, cells were left untreated or were treated with the TGFβ1 vehicle solution 
(0.2 μm filtered 4 mM HCl with 1 mg/ml of BSA). The plate returned to the incubator for 
an additional period of 24 hours.  
AB was then aseptically and directly added into the culture medium at a final concentration 
of 10%. Blanks consisted of only medium with 10% AB. Absorbance at both 570 nm and 
600 nm was read 4, 12, 24 and 36 hours microplate reader Infinite M200 (Tecan, 
Barcelona, Spain). Percentage of AB reduction was calculated as depicted on Figure 6. 
 
 
 
Figure 6 | Equation applied to calculate the percentage of reduction of AB. 
O1: Molar extinction coefficient (E) of oxidized AB (Blue) at 570nm; O2: E of oxidized AB at 600nm; R1: E of reduced 
AB (Red) at 570nm; R2: E of reduced AB at 600nm; A1:  Absorbance of test wells at 570nm; A2: Absorbance of test 
wells at 600nm; N1: Absorbance of negative control well at 570nm; N2: Absorbance of negative control well at 600nm. 
Percentage of reduction of AB = 
(       )  (       )
(      )  (      )
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3.14 MIGRATION ASSAY 
Cell migration was assessed using HTS Transwell-96 Permeable Support Plates (VWR 
International, Carnaxide, Portugal) with a polyester membrane with 8.0 μm pore size 
(Figure 19 in Appendix).  
Transfected cells were trypsinized and centrifuged at 1000 rpm for 3 minutes at 22°C. 
After cell resuspension in serum-free medium, cells were counted as stated in 3.4., and 
2.5x10
3
 cells/well of cell suspension were seeded on the top of the polyester membranes in 
the seeder plate.  The seeder plate was immersed in a reservoir plate fulfilled with 150 μl 
of serum-free medium and plates were incubated in a 5% CO2 humidified incubator at 
37°C. After 4 hours of initial cell attachment, 5 or 20 ng/ml of TGFβ1 were added to the 
reservoir plate, or cells were left untreated. The plate returned to the incubator for an 
incubation period of 24 hours to let cells migrate through the polyester membrane.  
At this time, cells that did not migrate were removed from the seeder plate with a cotton 
swab. AB was then aseptically added into the culture medium in the reservoir plate at a 
final concentration of 10%. Blanks consisted of only medium with 10% AB Absorbance at 
both 570 nm and 600 nm was read 24 hours microplate reader Infinite M200 (Tecan, 
Barcelona, Spain). 
3.15 DATA ANALYSIS 
Absorbance measurements were used to calculate the percentage of reduction of AB. Data 
were presented as mean ± standard deviation (SD) or mean ± 95% confidence interval (the 
chosen error bar was stated in the legend for each case).  
Significant differences between median proliferation and migration rates of the different 
groups (non-transfected cells, TCTEX1D4 transfected cells, and TCTEX1D4-RVSA 
transfected cells) were evaluated with the Kruskal–Wallis one-way analysis of variance 
test (α=0.05).The same test was used to assess significant differences between the groups 
in response to TGFβ treatment.  
This first approach was followed by multiple comparisons using the Mann-Whitney U test 
with Bonferroni correction (α=0.017) to compare TCTEX1D4 and TCTEX1D4-RVSA 
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groups versus non-transfected cells and also TCTEX1D4 versus TCTEX1D4-RVSA 
transfected cells. IBM SPSS Statistics 21 software was used to compute all tests. 
28 
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RESULTS 
The initial experiments of optimization were performed using RWPE-1, LNCaP, and PC-3 
cells. After a kind donation from Dr. Ricardo Pérez-Tomás, we started to use PNT-2 cells 
as a benign control in the experiments. 
4.1 TCTEX1D4 AND PPP1 ARE PRESENT IN HUMAN PROSTATE CANCER 
CELLS  
TCTEX1D4 expression was already described in several tissues, including ovary, spleen, 
lung, placenta, and kidney [70]. Its presence was also observed in a number of cell lines, as 
human umbilical vein endothelial cells (HUVECs), human dermal microvascular 
endothelial cell line (HMEC-1), hepatocellular carcinoma cells (HepG2), breast cancer 
cells (T47D), and large cell lung cancer (LCLC) [67]. 
To confirm the presence of TCTEX1D4 in human prostate cells, a preliminary experiment 
was performed using a polyclonal antibody, raised in rabbit, against the C-terminal of 
TCTEX1D4 (CBC8C, Appendix). In LNCaP and PC-3 cells we observed a band at around 
28 kDa, corresponding to the full-length TCTEX1D4 (Figure 7). The protein predicted 
molecular weight, nonetheless, is of 23.4 kDa. This band shift might be a consequence of 
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post-translational modifications, such as phosphorylation and/or glycosylation as already 
mentioned by Korrodi et. al [70]. The expression of TCTEX1D4 in normal prostate cells 
RWPE-1 was only detectable after protein concentration by immunoprecipitation (data not 
shown).  
 
Figure 7 | TCTEX1D4 and PPP1CC are present in human PCa cell lines LNCaP and PC-3.  
The screening (100 μg) of TCTEX1D4 and PPP1CC isoform was performed using CBC8C and CBC3C antibodies, 
respectively. Extracts were prepared in 1% SDS. pET vector alone (pET-) was used as negative control and pET-
TCTEX1D4 (pET+)  was used as positive control. 
Despite the fact that PPP1 is a ubiquitously expressed protein, we also assessed the 
expression of PPP1CC in the same immunoblot. The blot was incubated with a polyclonal 
antibody, raised in rabbit, against the C-terminal of PPP1CC isoform (CBC3C). A band 
was detected at 37 kDa, in both cell lines, according to the PPP1 predicted molecular 
weight (Figure 7). Additionally, PPP1CA expression in these cell lines was also confirmed 
by Western blot and both PPP1 isoforms were also observed in RWPE-1 and PNT-2 (data 
not shown). 
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4.2 OPTIMIZATION OF THE TRANSFECTION METHOD 
The interaction between TCTEX1D4 and PPP1 was previously established in a testis yeast-
two hybrid and was further confirmed by yeast co-transformation and co-
immunoprecipitation [70]. Once we have confirmed the presence of both TCTEX1D4 and 
PPP1 in human prostate cells, we focused our attention in the possible influence of this 
complex in cell proliferation and migration. To achieve the main objectives, we transfected 
human prostate cells with Myc-TCTEX1D4 or Myc-TCTEX1D4-RVSA plasmids. Hence, 
a first approach aimed to optimize cell transfection conditions. 
A pilot experiment was performed using different amounts of DNA (1μg, 2μg, and 3μg) 
and Lipofectamine 2000 (2μl, 4μl, and 6μl) and also different times of transfection (8 and 
24 hours) in low-passage RWPE-1, LNCaP and PC-3 cells. The TE obtained was assessed 
both by Western blot and immunofluorescence.  
Results obtained when cells were transfected with 1 μg of Myc-TCTEX1D4 or Myc-
TCTEX1D4-RVSA to 2 μl of Lipofectamine 2000, as well as when transfection occurred 
for 8 hours, are not shown due to the few transfected cells observed. For the other cases, 
blots showed a band at around 28 kDa that corresponds to the TCTEX1D4 expressed by 
transfected cells 24 hours after transfection (Figure 8).  
 
Figure 8 | Immunoblot analysis of Myc-TCTEX1D4 and Myc-TCTEX1D4-RVSA transfection in RWPE-1, PC-3, 
and LNCaP cells using different amounts of DNA and Lipofectamine 2000 (ratio 1:2).  
Cells were transfected for 24 hours using Lipofectamine 2000. Extracts were prepared in 1% SDS and 50 μg of protein 
were run in a 15% polyacrylamide gel. Blots were incubated with mouse anti-Myc-tag antibody. Cells alone and cells 
transfected with the empty vector pCMV-Myc were used as negative controls.  
Results  The role of TCTEX1D4/PPP1 complex in cell proliferation and migration 
 
32 
 
This analysis was complemented with a quantitative study by immunofluorescence. In this 
case, PNT-2 cell line was already available to be included in the experiment. Cells were 
stained with the c-Myc mouse monoclonal primary antibody and the Texas Red goat anti-
mouse secondary antibody; nuclei were stained with DAPI. The number of transfected 
cells was estimated using an epifluorescence microscope, under a magnification of 20x. 
The best TE was achieved when cells were transfected for 24 hours with 3 μg of DNA to 
6μl of Lipofectamine 2000, for both Myc-TCTEX1D4 and Myc-TCTEX1D4-RVSA 
plasmids (Figure 9). For this reason, all the subsequent experiments were carried out under 
these conditions.  
 
Figure 9 | Transfection efficiency for each vector (TCTEX1D4/TCTEX1D4-RVSA) in each cell line. 
Cells were transfected with 3 μg of DNA and 6 μl of Lipofectamine 2000 for 24h. The graph shows the average number 
of transfected cells determined by fluorescence microscopic visualization. Data represent the mean ± standard deviation 
(SD) of three independent experiments. RWPE-1 TCTEX1D4: 36.35±1.85%; RWPE-1 TCTEX1D4-RVSA: 
35.34±3.54%; PNT-2 TCTEX1D4: 31.85±2.07%; PNT-2 TCTEX1D4-RVSA: 32.40±1.72%; LNCaP TCTEX1D4: 
33.37±13.65%; LNCaP TCTEX1D4-RVSA: 30.87±6.23%; PC-3 TCTEX1D4: 42.04±9.68%; PC-3 TCTEX1D4-RVSA: 
43.87±9.38%. 
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4.3 IMMUNOFLUORESCENCE ANALYSIS OF TRANSFECTED CELLS 
The immunofluorescence analysis also enabled the comparison of transfected TCTEX1D4 
and mutant TCTEX1D4 localization and distribution (Figure 10).   
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Figure 10 | Fluorescence microscopy visualization and intracellular distribution of Myc-TCTEX1D4 and Myc-
TCTEX1D4-RVSA in transfected cells. 
RWPE-1, PNT-2, PC-3, and LNCaP cells were transfected with Myc-TCTEX1D4 or Myc-TCTEX1D4-RVSA (red), 
labeled with c-Myc mouse monoclonal antibody and Texas Red anti-mouse secondary antibody. Nuclei (blue) were 
stained with DAPI. Images were analyzed by an epifluorescence microscope. Scale bars:20 µm.  
Outwardly, there is no significant difference between the distribution of wild type and 
mutant TCTEX1D4. But interestingly, the stained pattern of RWPE-1 cells is distinct when 
compared to the other cell lines. The subcellular localization of transfected 
TCTEX1D4/TCTEX1D4-RVSA in PNT-2, PC-3, and LNCaP was dispersed in the cell 
nucleus and cytoplasm. Transfected TCTEX1D4/TCTEX1D4-RVSA in RWPE-1 appears 
to be mainly confined to the perinuclear space and cytoplasmic membrane.  
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4.4 ESTABLISHMENT OF TGFβ1 CONCENTRATIONS FOR CELL TREATMENT 
The next step in our workflow aimed to establish the ideal concentrations of TGFβ1 to 
treat human prostate cells. To start with, we revised the literature available in PubMed, 
using the terms “transforming-growth factor beta 1”, “prostate”, and “cell proliferation” as 
keywords (Table 2). 
Table 2 | Summary of the information found during the PubMed search. 
Cell line TGFβ1 concentration Cellular effect 
   
RWPE-1 10 ng/ml  
(serum-free, 8h) 
Proliferation: decreased proliferation 
[71]
. 
   
PNT-2 1, 2, or 5 ng/ml 
(serum-free, 48h) 
Proliferation: dose-dependent growth inhibition 
[72]
. 
   
LNCaP 1 ng/ml 
(48h) 
Migration: no effect 
[73]
. 
1 ng/ml  
(5% FBS, 18h) 
Proliferation: no inhibitory effect. Instead, there 
was a slight increase comparing to the controls 
[74]
. 
10 ng/ml  
(5% FBS, 18h) 
Proliferation: no effect 
[74]
. 
   
PC-3 1 ng/ml 
(48h) 
Migration: increased migration 
[73]
.  
1 ng/ml 
(48h) 
Proliferation: no inhibitory effect. Instead, there 
was a slight increase comparing to the controls 
[73]
. 
Migration: Increased migration 
[74]
. 
5 ng/ml 
(48h) 
Migration: increased migration 
[74]
. 
   
 
Taking into account this information, we performed a pilot experiment to test different 
conditions. The first attempt was carried out in medium supplemented with 10% FBS. 
Cells were treated with different concentrations of TGFβ1 (1 ng/ml, 5 ng/ml, and 10 ng/ml) 
for 48 hours and, afterward, cell proliferation was measured using AB. The percentage of 
reduction of AB, and consequently the cell proliferation, was calculated by applying the 
equation on Figure 6. 
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Due to the virtually no effect of TGFβ1 in cell proliferation, a next try was accomplished 
in serum-free medium with a lower cell plating density using a low (5 ng/ml) and a high 
(20 ng/ml) concentration of TGFβ1. Cell proliferative behavior in each condition is 
depicted in Figure 11. 
 
 
 
 
 
 
 
 
A 
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Figure 11 | Proliferation of PNT-2, LNCaP, and PC-3 cells in response to TGFβ1.  
Cells were seeded in medium supplemented with 10% FBS or in serum-free medium. Each cell line was exposed to a 24 
hours treatments with different concentrations of TGFβ1. Cells with no treatment were used as negative control. The 
graph shows the average percentage of reduction of AB for PNT-2 (A), LNCaP (B), and PC-3 (C). Data represent the 
mean ± SD for two replicates of each condition. Mean values ± Standard Deviation were as follows:  A) Medium + 10% 
B 
C 
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FBS – Cells: 64.69±0.25%; TGFβ1 1 ng/ml: 65.42±2.76%; TGFβ1 5 ng/ml: 65.80±3.46%; TGFβ1 10 ng/ml: 
66.68±15.37%. Serum-free medium – Cells: 60.39±6.29%; TGFβ1 5 ng/ml: 47.73±6.48%; TGFβ1 20 ng/ml: 
65.05±0.95%. B) Medium + 10% FBS – Cells: 47.78±2.43%; TGFβ1 1 ng/ml: 47.82±14.28%; TGFβ1 5 ng/ml: 
47.26±1.73%; TGFβ1 10 ng/ml: 44.63±0.36%. Serum-free medium – Cells: 43.24±9.18%; TGFβ1 5 ng/ml: 
33.34±8.58%; TGFβ1 20 ng/ml: 45.79±0.24%. C) Medium + 10% FBS – Cells: 52.54±0.02%; TGFβ1 1 ng/ml: 
51.96±9.47%; TGFβ1 5 ng/ml: 51.99±3.76%; TGFβ1 10 ng/ml: 51.78±0.45%. Serum-free medium – Cells: 
55.89±2.11%; TGFβ1 5 ng/ml: 55.80±5.56%; TGFβ1 20 ng/ml: 58.95±9.26%. 
 
Given these results, the subsequent experiments were performed under a serum-free 
environment with 5 ng/ml or 20 ng/ml of TGFβ1. 
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4.5 PROLIFERATION OF TRANSFECTED CELLS IN RESPONSE TO TGFβ1 
In furtherance of determine the effect of TCTEX1D4/PPP1 complex in human prostate 
cells proliferation, cells were transfected with wild type TCTEX1D4 or a mutant form that 
present an alteration in a residue of the PPP1 binding domain. This alteration (from RVSF 
to RVSA) allows a 35% diminishment of PPP1 binding to TCTEX1D4.  
Transfected cells where subjected to a 48 hours treatment with TGFβ (5 ng/ml or 20 
ng/ml). Non-transfected cells either with no treatment or treated with the vehicle (solution 
where TGFβ were reconstituted) were used as negative controls. Cell proliferation was 
monitored with the cell dye AB at several times of the experiment upon the addition of 
TGFβ1. The results showed the mean percentage of reduction of AB for three independent 
experiments (each of three replicates) at the end-point of the experiment (48 hours). 
Inside cells, AB is reduced in by mitochondrial enzymes, as flavin mononucleotide 
dehydrogenase, flavin adenine dinucleotide dehydrogenase, nicotinamide adenine 
dehydrogenase, and cytochromes, and also by cytosolic and microsomal enzymes. 
Resofurin, a red-fluorescent compound, is excreted to the medium, resulting in color 
change from blue to pink. Thus, the rate of reduction based on color changes reflects the 
number of viable cells [75]. 
4.5.1 PNT-2 
As depicted in Figure 12, both TCTEX1D4 and TCTEX1D4-RVSA transfected cells 
presented a lower proliferation rate (55.35% and 40.96%, respectively) when compared 
with non-transfected cells (71.47%). Kruskal-Wallis test confirmed the existence of 
statistically significant differences p=0.009. 
The addition of TGFβ1 did not produced significant effects in any of the conditions. 
However, the addition of TGFβ1 to the TCTEX1D4 transfected cells decreased the 
proliferation rate (to 50.89% and 69.16%, depending on the concentration) when compared 
to the vehicle control (93.13%). The same occurred in a lesser extent in TCTEX1D4-
RVSA transfected cells, where the vehicle control presented a proliferation of 49.72% and 
cells treated with TGFβ1 decreased the proliferation in a dose-dependent manner to 44.0% 
and 38.92%. 
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Figure 12 | Proliferation of PNT-2 transfected cells in response to TGFβ1.  
Cells were treated with TGFβ1 (5 ng/ml or 20 ng/ml), left untreated or treated with the vehicle for 48 hours. The graph 
shows the average percentage of reduction of AB. Data represent the mean and 95% confidence intervals (95% CI) for 
three independent experiments, each of three replicates for each condition. Mean value is displayed for each condition. 
Mean values ± Standard Deviation were as follows: Cells: 71.47±30.26%; cells + vehicle: 61.16±45.26; cells + TGFβ1 5 
ng/ml: 55.83±39.64; cells + TGFβ1 20 ng/ml: 64.37±26.68%;  TCTEX1D4: 55.35±20.31; TCTEX1D4 + vehicle: 
93.13±37.32; TCTEX1D4 TGFβ1 5 ng/ml: 50.89±14.36; TCTEX1D4 TGFβ1 20 ng/ml: 69.16±43.77; TCTEX1D4-
RVSA: 40.86±19.04; TCTEX1D4-RVSA + vehicle: 49.72±13.13 ;TCTEX1D4-RVSA TGFβ1 5 ng/ml: 44.40±27.52; 
TCTEX1D4-RVSA TGFβ1 20 ng/ml: 38.92±18.31.Differences in the variable “transfected protein” were statistically 
significant (p = 0.009). 
4.5.2 LNCaP 
As can be observed in Figure 13, LNCaP cells transfected with TCTEX1D4 or 
TCTEX1D4-RVSA presented a lower proliferation rate (41,62% and 32,53%, respectively) 
when compared to non-transfected cells (52,25%). However, differences were not 
statistically significant.  
TGFβ1 treatment narrowed down the proliferation of cells in all conditions when compared 
with the vehicle control, but not in a significant way. 
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Figure 13 | Proliferation of LNCaP transfected cells in response to TGFβ1.  
Cells were treated with TGFβ1 (5 ng/ml or 20 ng/ml), left untreated or treated with the vehicle for 48 hours. The graph 
shows the average percentage of reduction of AB. Data represent the mean and 95% confidence intervals (95% CI) for 
three independent experiments, each of three replicates for each condition. Mean value is displayed for each condition. 
Mean values ± Standard Deviation were as follows: Cells: 52.25±24.026%; cells + vehicle: 57.22±26.25; cells + TGFβ1 
5 ng/ml: 45.30±24.95; cells + TGFβ1 20 ng/ml: 49.68±24.41%;  TCTEX1D4: 41.62±16.21; TCTEX1D4 + vehicle: 
46.25±14.78; TCTEX1D4 TGFβ1 5 ng/ml: 38.12±15.08; TCTEX1D4 TGFβ1 20 ng/ml: 38.57±15.58; TCTEX1D4-
RVSA: 32.53±14.94; TCTEX1D4-RVSA + vehicle: 49.76±13.09 ;TCTEX1D4-RVSA TGFβ1 5 ng/ml: 41.00±25.94; 
TCTEX1D4-RVSA TGFβ1 20 ng/ml: 44.37±25.73. 
4.5.3 PC-3 
As depicted in Figure 14, PC-3 cells transfected with TCTEX1D4 or TCTEX1D4-RVSA 
presented a lower proliferation rate (38.64% and 34.34%, respectively) when compared to 
non-transfected cells (57.38%). Kruskal-Wallis test confirmed the existence of statistically 
significant differences p<0.001. 
The addition of TGFβ1 produced almost no effect in non-transfected cells. In TCTEX1D4 
transfected cells, nevertheless, it decreased cell proliferation capability (38.15% and 
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43.11%, depending on concentration) when compared to the vehicle control (52.59%). In 
TCTEX1D4-RVSA transfected cells, high concentrations of TGFβ1 appeared to induce 
cell proliferation. However, any of the differences observed were statistically significant. 
 
Figure 14 | Proliferation of PC-3 transfected cells in response to TGFβ1.  
Cells were treated with TGFβ1 (5 ng/ml or 20 ng/ml), left untreated or treated with the vehicle. The graph shows the 
average percentage of reduction of AB. Data represent the mean and 95% confidence intervals (95% CI) for three 
independent experiments, each of three replicates for each condition. Mean value is displayed for each condition. Mean 
values ± Standard Deviation were as follows: Cells: 57.38±33.23%; cells + vehicle: 56.18±32.68; cells + TGFβ1 5 ng/ml: 
56.94±34.25; cells + TGFβ1 20 ng/ml: 53.42±29.31%;  TCTEX1D4: 38.64±20.60; TCTEX1D4 + vehicle: 52.59±5.38; 
TCTEX1D4 TGFβ1 5 ng/ml: 38.15±20.29; TCTEX1D4 TGFβ1 20 ng/ml: 43.11±20.30; TCTEX1D4-RVSA: 
34.34±20.37; TCTEX1D4-RVSA + vehicle: 35.51±6.59 ;TCTEX1D4-RVSA TGFβ1 5 ng/ml: 32.06±16.12; 
TCTEX1D4-RVSA TGFβ1 20 ng/ml: 43.63±29.57. Differences in the variable “transfected protein” were statistically 
significant (p < 0.001).  
4.5.4 ADDITIONAL ANALYSIS OF STATISTICAL SIGNIFICANT DIFFERENCES 
The results from the Kruskal-Wallis test state that there are differences between the median 
proliferation rates among non-transfected cells, TCTEX1D4 transfected cells, and 
TCTEX1D4-RVSA transfected cells populations. To further analyze these differences, we 
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performed the Mann-Whitney U test with Bonferroni correction (α=0.017) in order to 
conduct multiple comparisons between groups.  
The results show that for PNT-2 cells only the comparison between TCTEX1D4 and 
TCTEX1D4-RVSA populations reached statistical significance (p=0.004). Thus, the 
proliferation rate of PNT-2 cells when the ability to binding to PPP1 is decreased is 
significantly lower than when cells express wild type TCTEX1D4. 
For PC-3 cells, all multiple comparisons performed show statistical significance (non-
transfected cells versus TCTEX1D4 transfected cells: p=0.001; non-transfected cells 
versus TCTEX1D4-RVSA transfected cells: p=0.002; and TCTEX1D4 transfected cells 
versus TCTEX1D4-RVSA transfected cells: p=0.007). Hence, it appears that cells exhibit a 
lower proliferation rate when express wild type TCTEX1D4, but this decrease is even 
more pronounced when TCTEX1D4 is mutated in the RVSF motif, compromising its 
binding to PPP1. 
4.6 MIGRATION OF TRANSFECTED CELLS IN RESPONSE TO TGFβ1 
To unravel the influence of TCTEX1D4/PPP1 complex in cell migration, human prostate 
cells were transfected with the plasmids Myc-TCTEX1D4 and Myc-TCTEX1D4-RVSA 
for the reasons already mentioned in proliferation. After that, cells were seeded in the 
seeder plate of the HTS Transwell Permeable Support and allowed to migrate for 24 hours 
through a microporous membrane in response to low (5 ng/ml) or high (20 ng/ml) 
concentrations of TGFβ1.  
The number of migratory cells in the reservoir plate was then assessed using AB and the 
percentage of reduction of AB was calculated according to Figure 10 [76]. 
4.6.1 PNT-2 
Cells transfected with TCTEX1D4-RVSA showed a slight improvement in their migratory 
potential (18.53%) when compared to control cells (14.90%) or cells transfected with 
TCTEX1D4 (16.00%), as depicted in Figure 15.  
The addition of higher concentrations of TGFβ1 to the experimental environment 
generated a tiny decrease in the migration of PNT-2 (from 15.12% to 12.44%). In 
TCTEX1D4, TGFβ1 decreased the cell migratory behavior in a dose-dependent manner 
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(from 18.77% to 16.84% and 15.87%). On the other hand, higher concentrations of TGFβ1 
potentiate the migratory potential of TCTEX1D4 transfected cells (22.53% compared with 
17.43% of the vehicle control). However, any of the differences were statistically 
significant. 
 
 
Figure 15 | Migration of PNT-2 transfected cells in response to TGFβ1.  
Cells were treated with TGFβ1 (5 ng/ml or 20 ng/ml), left untreated or treated with the vehicle for 24 hours. The graph 
shows the average percentage of reduction of AB. Data represent the mean ± SD for two independent experiments, each 
of two replicates for each condition. Mean value is displayed for each condition. Mean values ± Standard Deviation were 
as follows: Cells: 14.90±6.13%; cells + vehicle: 15.12±4.04; cells + TGFβ1 5 ng/ml: 15.25±7.32; cells + TGFβ1 20 
ng/ml: 12.44±2.99%;  TCTEX1D4: 16.00±5.22; TCTEX1D4 + vehicle: 17.43±7.50; TCTEX1D4 TGFβ1 5 ng/ml: 
16.33±6.34; TCTEX1D4 TGFβ1 20 ng/ml: 22.53±10.20; TCTEX1D4-RVSA: 18.53±8.92; TCTEX1D4-RVSA + 
vehicle: 7.15±13.13 ;TCTEX1D4-RVSA TGFβ1 5 ng/ml: 16.84±7.03; TCTEX1D4-RVSA TGFβ1 20 ng/ml: 15.87±5.46. 
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4.6.2 LNCaP 
As can be observed in Figure 16, there is virtually no difference among the migratory 
behavior of LNCaP cells (17.05%), TCTEX1D4 transfected cells (18.76%), and 
TCTEX1D4-RVSA cells (18.43%).  
The addition of TGFβ1 appears to reduce the migration rate in all conditions, but 
differences were not significant. 
 
 
Figure 16 | Migration of LNCaP transfected cells in response to TGFβ1.  
Cells were treated with TGFβ1 (5 ng/ml or 20 ng/ml), left untreated or treated with the vehicle for 24 hours. The graph 
shows the average percentage of reduction of AB. Data represent the mean ± SD for two independent experiments, each 
of two replicates for each condition. Mean value is displayed for each condition. Mean values ± Standard Deviation were 
as follows: Cells: 17.05±7.19%; cells + vehicle: 22.85±10.46; cells + TGFβ1 5 ng/ml: 18.52±8.39; cells + TGFβ1 20 
ng/ml: 18.48±7.87%;  TCTEX1D4: 18.76±7.46; TCTEX1D4 + vehicle: 20.35±6.30; TCTEX1D4 TGFβ1 5 ng/ml: 
16.55±6.03; TCTEX1D4 TGFβ1 20 ng/ml: 18.96±7.54; TCTEX1D4-RVSA: 18.43±6.98; TCTEX1D4-RVSA + vehicle: 
20.83±5.39 ;TCTEX1D4-RVSA TGFβ1 5 ng/ml: 19.18±8.27; TCTEX1D4-RVSA TGFβ1 20 ng/ml: 17.77±7.13. 
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4.6.3 PC-3 
As depicted in Figure 17, the transfection with TCTEX1D4 or its mutant did not produce 
any alteration in cell migration rate.  
The addition of TGFβ1 resulted in a decrease in migration in both non-transfected cells and 
cells transfected with TCTEX1D4. In TCTEX1D4-RVSA transfected cells, the addition of 
TGFβ1 did not produced any alteration in the migration rates. 
  
Figure 17 | Migration of PC-3 transfected cells in response to TGFβ1.  
Cells were treated with TGFβ1 (5 ng/ml or 20 ng/ml), left untreated or treated with the vehicle for 24 hours. The graph 
shows the average percentage of reduction of AB. Data represent the mean ± SD for two independent experiments, each 
of two replicates for each condition. Mean value is displayed for each condition. Mean values ± Standard Deviation were 
as follows: Cells: 15.14±5.30%; cells + vehicle: 19.78±1.07; cells + TGFβ1 5 ng/ml: 14.51±4.25; cells + TGFβ1 20 
ng/ml: 16.35±6.07%;  TCTEX1D4: 15.30±4.22; TCTEX1D4 + vehicle: 16.77±5.69; TCTEX1D4 TGFβ1 5 ng/ml: 
15.08±5.00; TCTEX1D4 TGFβ1 20 ng/ml: 14.61±5.58; TCTEX1D4-RVSA: 15.56±5.91; TCTEX1D4-RVSA + vehicle: 
17.53±7.69 ;TCTEX1D4-RVSA TGFβ1 5 ng/ml: 17.09±7.64; TCTEX1D4-RVSA TGFβ1 20 ng/ml: 17.50±8.94. 
 
47 
 
DISCUSSION 
In the present study we aimed to unravel the effect of TCTEX1D4 and the role of its 
binding to PPP1 in cell proliferation and migration. We took advantage of two plasmids 
[70], one expressing wild type TCTEX1D4 and the other expressing a mutant form in the 
PPP1 binding motif from RVSF to RVSA. This mutant TCTEX1D4 binds to PPP1 with a 
35% less efficiency.  
To achieve our main goal, we firstly performed several experiments in order to optimize 
cell transfection method with Lipofectamine 2000. With the selected conditions, we were 
able to achieve transfection efficiencies above 30% for all cell lines, which is already 
suitable to respond our main goals.  
As TCTEX1D4 was found to interfere with TGFβ signaling pathway, we stimulated cells 
with TGFβ1 in order to achieve a broader comprehension on TCTEX1D4 function. TGFβ1 
is a cytokine known to inhibit proliferation of epithelial cells. Actually, it has been 
recognized as a challenging barrier to the development of cancer hallmarks, as it inhibits 
cell proliferation, migration and invasion, while promotes apoptosis, cell adhesion, and 
cellular differentiation. However, in late-stage tumors, the cellular machinery subverts the 
TGFβ signaling pathway in order to promote cancer progression.  
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In normal prostate cells, as well as in prostate cancer cells, TGFβ effects are, nevertheless, 
not well-established and some questions still in debate. PNT-2 cells have been described as 
being responsive to TGFβ1, and their proliferation was shown to be inhibited by its signal 
[72]. PC-3 cells have been referred as being partially responsive to the inhibitory effects of 
TGFβ1 due to the loss of TGFβ receptors with PCa progression [77]. LNCaP cells are the 
more debated ones; some authors defend that they are totally resistant to the anti-
proliferative effects of TGFβ1 and exhibit a complete absence of TβRI mRNA transcripts 
[77], whereas others demonstrated that they could be responsive in certain conditions [78]. 
Also, the differences in human prostate cells response to TGFβ1 appear to be extremely 
related to the TGFβ1 concentration used.  
In this study, using 5 ng/ml and 20 ng/ml of TGFβ1, we verified that: (1) in PNT-2 cells, 5 
ng/ml of TGFβ1 decreased cells proliferation as previously described [72], but cell 
proliferation returned to approximately normal levels when cells were exposed to 20 ng/ml 
TGFβ1; (2) LNCaP were responsive, presenting a decrease in proliferation in response to 
both concentrations of TGFβ1; (3) PC-3 were virtually non-responsive. In terms of 
migratory behavior, all the three cell lines showed a decrease in migration in response to 
TGFβ1, although this effect in PNT-2 was only observed with the highest concentration. 
However, these results are difficult to compare due to the variability associated to them. 
The presence of large error bars could be partially explained by differences in the 
transfection efficiency between independent experiments. Also, AB is sensible for as less 
as 50 cells. Thus, even small inconsistencies in cell counting, resuspension and consequent 
plating can result in slightly distinct absorbance measurements. That is way it is 
recommended to perform replicates of each measurement. So, to be sure of the effects of 
TGFβ1 in the cell lines used we should increase the number of measurements for each 
condition in order to decrease the associated error.  
In spite of the variability associated with our data, we obtained statistically significant data 
that allowed us to progress on the understanding of TCTEX1D4 and to understand the 
importance of its regulation via binding to PPP1. 
TCTEX1D4 as an anti-proliferative agent 
TCTEX1D4 is a dynein light chain protein whose function remains poorly understood. It 
has been proposed to be a player in the TGFβ signaling pathway. More precisely, 
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TCTEX1D4 binds to two TGFβ receptors, TβRII and endoglin, and retained them in the 
cellular membrane [67]. By this way, receptors cannot be internalized and the process of 
receptors recycling is compromised. This virtually culminates in the inhibition of Smad2/3, 
whose signal is known to lead to the acquisition of malignant capabilities in late-stage 
tumors, including invasiveness, migration, and metastasis formation [38, 39]. So, TCTEX1D4 
is expected to act as a tumor suppressor by inhibiting Smad2/3 signaling. In fact, the 
results obtained corroborate this hypothesis as TCTEX1D4 decreased cell proliferation in 
the three cell lines used, with the results being statistically significant for PNT-2 and PC-3 
cells.  
TGFβ1 addition decreased cell proliferation in cells transfected with TCTEX1D4 and 
TCTEX1D4-RVSA in almost all cell lines when compared to the control vehicle (the 
exception is a high concentration of TGFβ1 in PC-3 transfected with TCTEX1D4-RVSA, 
where proliferation seemed to be enhanced). However, these alterations were not 
significant. Taking into account the current theoretical knowledge about TCTEX1D4, if 
the more prominent mode of action of TCTEX1D4 in TGFβ signaling is achieved by the 
maintenance of TβRII receptors in the cell membrane, it is likely that they virtually 
become overcrowded and no more sites are available for ligand binding. Therefore, it is 
expected that the addition of TGFβ1 in TCTEX1D4 transfected cells produce limited anti-
proliferative effects. 
PPP1 acts as a ‘switch off’ of TCTEX1D4 activity 
Extensive bioinformatics analysis of TCTEX1D4 structure performed in our laboratory 
demonstrated that TCTEX1D4 presents many putative serine phosphorylation sites while 
no threonine or tyrosine phospho-sites were found. This indicates that serine 
phosphorylation might be a primarily mechanism for its regulation. PPP1 is a major 
phosphatase specific for serine and threonine residues, and accordingly, it was found the 
RVSF motif in the N-terminus of TCTEX1D4 [70]. Thus, this evidence suggests that 
TCTEX1D4 function might be regulated via dephosphorylation by PPP1.  
The mutation in one amino acid of the RVSF motif of TCTEX1D4 was previously shown 
to decrease the bind of TCTEX1D4 to PPP1 in about 35% [70]. Hence, TCTEX1D4-RVSA 
transfected cells mimic a state where there is an impairment of the formation of 
TCTEX1D4/PPP1 complex and, consequently, a putatively weakening in TCTEX1D4 
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dephosphorylation. The results indicate that cells transfected with the TCTEX1D4 mutant 
(TCTEX1D4-RVSA) showed an even more pronounced decrease in cell proliferation than 
TCTEX1D4 transfected cells in all cell lines.  So, it appears that when PPP1 binding to 
TCTEX1D4 is compromised and dephosphorylation of TCTEX1D4 may occurred in a less 
extended manner, the inhibitory effects of TCTEX1D4 in cell proliferation are promoted. 
Therefore, PPP1 dephosphorylation of TCTEX1D4 might constitute a ‘switch off’ of 
TCTEX1D4 function, contributing to cell proliferation.  
In accordance to the above mentioned idea in what concerns TGFβ1 effect in TCTEX1D4 
transfected cells, TGFβ1 effect in TCTEX1D4-RVSA should be even more limited as 
TCTEX1D4 activity is augmented. Instead, our results still demonstrate a decrease in cell 
proliferation ratio in TCTEX1D4-RVSA transfected cells, as already mentioned, with the 
only exception being PC-3 TCTEX1D4-RVSA transfected cells. Once again, any of these 
alterations were statistically significant.  
TCTEX1D4 as a regulator of PPP1 subcellular localization 
An alternative or complementary explanation for TCTEX1D4/PPP1 complex functionality 
would be the targeting of PPP1 by TCTEX1D4. PPP1C has been already shown to be a 
noticeable regulator of several membrane receptors. For instance, in TGFβ signaling, 
PPP1C is presented to ALK5 receptor by the docking protein SARA, a targeting also 
involves GADD34 and Smad7. As a result, ALK5 is dephosphorylated and there is an 
attenuation of ALK5-mediating signaling. Also, PPP1C is recruited by Smad7 to ALK1, 
inhibiting the signaling via Smad1/5/8.  
As TCTEX1D4 is a dynein light chain protein, responsible for cargo binding, it is likely to 
bind PPP1 and modulate its subcellular localization. Dynein motor complexes are 
responsible for retrograde transport so, TCTEX1D4 might be responsible for capture PPP1 
in the cell membrane and transport it to intracellular compartments. Once there, PPP1 
might dephosphorylate key molecules for PCa progression. In fact, it was already 
demonstrated that PPP1 directly dephosphorylates and attenuates two major tumor 
suppressors, p53 and pRb, whose deregulation has been associated with PCa [52, 79, 80].  
As so, it might be expected that the disruption of the complex formation between 
TCTEX1D4 and PPP1 compromised the transport of PPP1 from the periphery to more 
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central localizations within the cell. Hence, TCTEX1D4 may indirectly regulate PPP1 
function by determining its subcellular localization. 
TCTEX1D4 role in cell migration is still cloudy 
In contrast to proliferation, where TCTEX1D4 seems to assume an important function as 
regulator, in migration its effects appear to be almost insignificant with only minor 
differences being observed. However, we are not able to discard a role for TCTEX1D4 and 
also for the complex that it forms with PPP1 in cell migration, as the incubation time used 
may not be sufficient to produce any significant migration. Moreover, the lack of 
differences could be due to the high data variability observed. The number of 
measurements and independent experiments is still lower (two replicates for each sample 
of two independent experiments), which is translated in large error bars that make difficult 
to establish comparisons among conditions.  
For these reasons, migratory potential of TCTEX1D4 and TCTEX1D4-RVSA transfected 
cells should be assessed using other methods that could provide a real-time analysis of cell 
movement.  
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CONCLUSIONS 
The study of cell signaling pathways and respective alterations in pathological processes 
has been receiving increasing attention as it enables the identification of molecules that 
may constitute potential biomarkers for diseases and/or new therapeutical targets [18].  
The particular relevance of such study in PCa is not only due to the high incidence and 
prevalence levels that it currently assumes (and that tend to increase along with population 
aging), but also because it is a clinically silent disease, particularly in early stages [81]. 
Another problem in PCa management started with the widespread implementation PSA 
screening, which led to the diagnosis and treatment of several PCa cases that would not 
otherwise cause symptoms or threaten man’s life. Altogether, these problems determine a 
particular urgency in the establishment of a specific panel of biomarkers in body fluids that 
empowered the diagnosis and follow-up of patients, and the discovery of new therapeutic 
targets [18]. 
Evidences suggest that modulation of TGFβ signaling aid the control of tumor progression. 
Thus, several mediators of TGFβ signaling pathway have been regarded as interesting 
targets for PCa therapy. Actually, genistein, a compound that is already ongoing phase II 
of clinical trials, acts via activation of Smad1, in an ALK2-dependent way, thus 
suppressing PCa invasiveness [77]. On the other hand, efforts are now being made by 
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pharmaceutical companies to investigate the role of phosphoprotein phosphatases as 
therapeutical targets. However, because of the numerous functions of PPP1 catalytic 
subunit, the long-term usage of these enzyme inhibitors has been associated with 
nephrotoxicity and hepatotoxicity. For this reason, the adequate option seems to be 
targeting PIPs instead of protein phosphatases directly as they are more event, tissue and 
subcellular compartment specific [44].  
In this study we demonstrated that a recently described PIP, TCTEX1D4, is an anti-
proliferative agent, as it decreased human prostate cells proliferation. Moreover, we 
showed that the impairment of the complex formation between TCTEX1D4 and PPP1 
culminates in a more exacerbate anti-proliferative activity of TCTEX1D4. Therefore, PPP1 
may be an inhibitory regulator of TCTEX1D4 anti-proliferative actions. Alternatively, or 
in a complementary manner, TCTEX1D4 may indirectly regulate PPP1 function through 
modification of its subcellular localization. 
For this reasons, TCTEX1D4/PPP1 complex might constitute a new therapeutical target for 
PCa, as it is expected that its disruption by small molecules (e.g. peptides [47]) leads to a 
decrease of PCa cell proliferation.  
To further explore this hypothesis, studies with mutants that mimic the phosphorylation 
state of TCTEX1D4 and short hairpin ribonucleic acids (shRNAs) for TCTEX1D4 are 
already being performed in the laboratory. 
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APPENDIX 
8.1 PCMV-MYC VECTOR 
 
 
 
 
 
Figure 18 | Restriction map and multiple cloning site (MCS) of pCMV-Myc. 
The pCMV-Myc Mammalian Expression Vector (Clontech, Saint Germain-en-Laye, France) expresses proteins 
containing the N-terminal c-Myc epitope tag. The c-Myc epitope tag is well-characterized and highly immunoreactive. 
High-level expression in mammalian cells is driven from the human cytomegalovirus immediate early promoter/enhancer 
(PCMV IE). The vector contains an intron (splice donor/splice acceptor); the epitope tag; an MCS; and a polyadenylation 
signal from SV40.This vector also possesses the ampicillin resistance gene for selection in E. coli. 
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8.2 ANTIBODIES 
Table 3 | Antibodies used for both Western blotting and immunocytochemistry.  
Antibodies’ target and specific dilution is also stated. 
Primary 
antibody 
Target Dilution Use Secondary antibody Dilution 
CBC3C PPP1CC 1:5000 Western blotting Infrared IRDye-
labeled anti-rabbit 
1:5000 
CBC8C TCTEX1D4 1:50 Western blotting Infrared IRDye-
labeled anti-rabbit 
1:50 
Mouse anti-
Myc-tag 
Myc-tag 1:5000 Western blotting Infrared IRDye-
labeled anti-mouse 
1:5000 
c-Myc Myc-tag 1:5000 Immuno-
cytochemistry 
Texas Red goat anti-
mouse 
1:300 
 
8.3 BCA PROTEIN ASSAY STANDARDS 
Table 4 | Standards used in the BCA protein assay method.  
BSA, bovine serum albumin solution (2 mg/ml); SDS, sodium dodecyl sulfate; WR, working 
reagent. 
Standard BSA (μl) 1% SDS (μl) Protein mass (μg) WR (μl) 
P0 - 25 0 200 
P1 0.5 24.5 1 200 
P2 1 24 2 200 
P3 2.5 22.5 5 200 
P4 5 20 10 200 
P5 10 15 20 200 
 
8.4 CELL CULTURE MEDIA AND SOLUTIONS 
PBS (1X) 
For a final volume of 500 ml, dissolve one pack of BupH Modified Dulbecco’s Phosphate 
Buffered Saline Pack (Thermo Scientific, Bremen, Germany) in deionized H2O. Final 
composition: 
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 8 mM Sodium Phosphate  
 2 mM Potassium Phosphate  
 140 mM Sodium Chloride  
 10 mM Potassium Chloride  
Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
 
Complete RPMI-1640 Medium 
 RPMI-1640 (Gibco, Madrid, Spain) 7,945 g 
 NaHCO3 (Sigma-Aldrich, Sintra, Portugal) 0.425 g 
 1% Streptomycin/Penicillin/Amphotericin 
solution (Gibco, Madrid, Spain) 
10 ml  
 10% FBS (Gibco, Madrid, Spain) 100 ml  
Dissolve RPMI-1640 and NaHCO3 in deionized H2O. Adjust the pH to 7.2-7.3.  Adjust the 
volume to 500 ml with deionized H2O. Add Streptomycin/Penicillin/Amphotericin solution 
and FBS. Sterilize by filtering through a 0.2 μm filter and store at 4°C 
 
Complete Keratinocyte-Serum Free Medium (K-SFM) 
 K-SFM (Gibco, Madrid, Spain) 500 ml 
 BPE (Gibco, Madrid, Spain) 25 mg 
 EGF (Gibco, Madrid, Spain) 2.5 μg 
 1% Streptomycin/Penicillin/Amphotericin 
solution (Gibco, Madrid, Spain) 
10 ml  
 10% FBS (Gibco, Madrid, Spain) 100 ml  
For a final volume of 500 ml of K-SFM (Gibco, Madrid, Spain) add 0,05 mg/ml BPE 
(Gibco, Madrid, Spain) and 5 ng/ml EGF (Gibco, Madrid, Spain). Add 1% 
Streptomycin/Penicillin/Amphotericin solution and 10% FBS. Sterilize by filtering through 
a 0.2 μm filter and store at 4°C.  
 
1 mg/ml poly-L-ornithine solution (10X) 
For a final volume of 100 ml, dissolve in deionized H2O 100 mg of poly-L-ornithine 
(Sigma-Aldrich, Sintra, Portugal). Sterilize by filtering through a 0.2 μm filter and store at 
4°C.  
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TGFβ1 solution 
TGFβ1 (Sigma-Aldrich, Sintra, Portugal) was reconstituted using 0.2 μm filtered 4 mM 
HCl (Sigma-Aldrich, Sintra, Portugal) containing 1 mg/ml of BSA (Nzytech, Lisboa, 
Portugal). Stock solution (1 μg/ml) was stored at -20°C. 
 
8.5 IMMUNOFLUORESCENCE SOLUTIONS 
4% paraformaldehyde fixative solution 
For a final volume of 100 ml, add 4g of paraformaldehyde (Sigma-Aldrich, Sintra, 
Portugal) to 25 ml deionized H2O. Dissolve by heating the mixture at 58ºC while stirring. 
Add 1-2 drops of    1 M NaOH to clarify the solution and filter (with a 0.2 μm filter). Add 
50 ml of 2X PBS and adjust the volume to 100 ml with deionized H2O. 
 
Permeabilization solution  
 0.2% (v/v) Triton X-100 (Sigma-Aldrich, Sintra, Portugal) 
 1X PBS 
 
8.6 SDS-PAGE AND IMMUNOBLOTTING SOLUTIONS 
4X LGB (lower gel buffer) 
To 900 ml of deionized H2O add: 
 1.5 M Tris-HCl 181.65 g 
 4% SDS 4 g 
Mix until the solutes have dissolved. Adjust the pH to 8.9 and adjust the volume to 1L with 
deionized H2O. 
 
5X UGB (upper gel buffer) 
To 900 ml of deionized H2O add: 
 0.6 M Tris-HCl 75.69 g 
Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to 1L with 
deionized H2O. 
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30% Acrylamide/0.8% Bisacrylamide 
To 70 ml of deionized H2O add: 
 Acrilamide 29.2 g 
 Bisacrylamide 0.8 g 
Mix until the solutes have dissolved. Adjust the volume to 100 ml with deionized H2O. 
Filter through a 0.2 μm filter and store at 4 °C. 
 
10% APS (ammonium persulfate) 
In 10 ml of deionized H2O dissolve 1 g of APS. 
 
10% SDS (sodium dodecyl sulfate) 
In 10 ml of deionized H2O dissolve 1 g of SDS. 
 
(4X) Loading gel buffer 
 250 mM Tris-HCl solution (pH 6.8) 2.5 ml 
 8% SDS 0.8 g  
 40% Glycerol 4 ml  
 2% β-Mercaptoethanol  2 ml  
 0.01% Bromophenol blue 1 mg  
Adjust the volume to 10 ml with deionized H2O. Store in darkness at RT. 
 
1 M Tris (pH 6.8) solution 
To 150 ml of deionized H2O add: 
 Tris base 30.3 g 
Adjust the pH to 6.8 and adjust the final volume to 250 ml. 
 
10X Running Bbuffer 
 250 mM Tris-HCl 30.3 g  
 2.5 M Glycine 144.2 g  
 1% SDS 10 g  
Dissolve in deionized H2O, adjust the pH to 8.3 and adjust the volume to 1 L. 
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10X Transfer buffer 
 25 mM Tris-HCl 3.03 g  
 192 mM Glycine 14.41 g  
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume to 800 
ml with deionized H2O. Just prior to use add 200 ml of methanol (20%). 
 
10X TBS (Tris buffered saline) 
 10 mM Tris-HCl 12.11 g  
 150 mM NaCl  87.66 g  
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionized H2O. 
 
10X TBST (TBS + Tween) 
 10 mM Tris-HCl 12.11 g 
 150 mM NaCl 87.66 g  
 0.05% Tween 20 5 ml  
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionized H2O. 
 
Blocking solution 
TBST (1X) in 5% of low-fat milk. 
 
Antibody solution 
TBST (1X) in 3% of low-fat milk. 
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8.7 HTS TRANSWELL PERMEABLE SUPPORT 
 
Figure 19 | Scheme of Corning Transwell Permeable Supports.  
(VWR International, Carnaxide, Portugal). 
This system is constituted by an upper compartment (seeder plate) where cells are seeding, a lower compartment 
(reservoir plate) which can be accessed via windows in the insert wall, and a microporous membrane through which cells 
are able to migrate. Different membrane types, pore sizes, and pore density are available.   
  
